Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, European Partners Complete Registration for Array-based MINDACT Trial


By Justin Petrone

Dutch test maker Agendia and its nonprofit research partners said this week that they have completed patient recruitment for a trial that will determine whether the company's array-based MammaPrint test is better than standard criteria in selecting breast cancer patients for adjuvant chemotherapy.

The company's research partners for the 6,000-patient Microarray in Node Negative and 1-3 Positive Lymph Node Disease, or MINDACT, trial are the European Organization for Research and Treatment of Cancer and the Breast International Group.

Agendia CEO Bernhard Sixt said in a statement that the completion of patient recruitment is a "major milestone" for the trial.

"If MammaPrint is ultimately shown to predict individual patient response to the trial-specific cancer therapies currently on the market, it will likely create significant and valuable synergies for the manufacturers of these drugs by improving treatment success rates," Sixt said.

He also said that information from the trial could be used to generate "new specific companion diagnostics" that can be added to the company's offering.

More than 6,600 patients in 111 institutions across nine countries were enrolled from February 2007 to July 2011 to take part in MINDACT, the partners said. MINDACT is investigating the clinical value of Agendia's MammaPrint test as compared to standard clinicopathological criteria for the selection of breast cancer patients for adjuvant chemotherapy.

The study aims to provide further evidence that breast cancer patients with low recurrence risk as determined by MammaPrint may not need chemotherapy. "This would spare patients from burdensome side effects without increasing the risk of metastasis or reducing survival," the partners said.
Additionally, the study is designed to show whether MammaPrint can predict patient response to specific therapies.

Agendia's MammaPrint test uses an expression signature from 70 genes to help physicians decide whether breast cancer is likely to recur. The US Food and Drug Administration cleared the test in 2007. Agendia has offered its assay as a service via its labs in Amsterdam and Irvine, Calif.

MINDACT is a multi-center, prospective, phase III randomized study comparing Agendia's MammaPrint with "Adjuvant! Online," a clinical-pathological prognostic tool to select patients with negative or 1-3 positive nodes for adjuvant chemotherapy in breast cancer. Novartis, Roche, and Sanofi-Aventis are all funding the MINDACT trial.

The test is also being evaluated in the US National Cancer Institute-sponsored I-SPY II (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis) study, which is designed to predict therapeutic response in the neoadjuvant setting. Researchers in that trial are using Agendia's whole-genome microarray platform to develop oncologic therapies paired with biomarkers. Abbott, Amgen, Pfizer, J&J, Roche, and Eli Lilly are all participating in the trial.

Details about when the study would be completed were not discussed.

Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.